Leaps by Bayer, the investment arm of global life sciences company Bayer, has partnered with Khloris Biosciences, a biotechnology company, to revolutionize cancer treatment. Their joint mission is to develop groundbreaking anti-cancer vaccines using human induced pluripotent stem cells (iPSCs). This cutting-edge technology holds immense potential in the fight against cancer, aiming to both prevent and cure this devastating disease.

The iPSC-based vaccination approach offered by Leaps and Khloris Biosciences promises a unique strategy for cancer treatment, engaging a comprehensive anti-tumor response. By harnessing the power of stem cells, they are working to create first-in-class vaccines that have the ability to target cancer in ways previously unexplored. Led by a distinguished Board of Directors and supported by esteemed Scientific Advisors, including leading cancer research professionals, Khloris Biosciences is dedicated to pushing the boundaries of medical innovation.

Investors and individuals passionate about advancing cancer research can find opportunities to get involved and learn more about the groundbreaking work being done by Leaps and Khloris Biosciences. Discover more about their mission and explore career opportunities at Khloris Biosciences, a company committed to revolutionizing cancer treatment for a better future